Start Your Search
P3.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 981)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
P3.15-10 - Survival Impact of Peripheral Blood Ratios in Lung Cancer According Clinical Stage (ID 14061)
12:00 - 13:30 | Author(s): Jesus Schwarz
Lung cancer represents one of the most frequent and letal neoplasms in many regions, where most patients are still diagnosed as advanced disease, and many biomarkers have been studied unsuccessfully. Peripheral blood ratios as Neutrophil-to-lymphocyte ratio (NLR), Monocyte-to-lymphocyte ratio (MLR) and Platelets-to-lymphocyte ratio (PLR) have been studied as potential biomarkers of systemic inflammation but cut-off values are still difficult to stablish. We explored the survival impact of different cut-off values according clinical stages in lung cancer.a9ded1e5ce5d75814730bb4caaf49419 Method
We analyzed medical records of 193 patients with lung cancer treated at ONCOSALUD–AUNA 2011-2014. Peripheral blood data was obtained retrospectively from the first medical visit and we calculated optimal cut-off values using the maximally selected rank statistics according every clinical stage (CS). Overall survival (OS) was evaluated using Kaplan-Meier method and survival curves comparison was performed using log-rank test or Breslow.4c3880bb027f159e801041b1021e88e8 Result
Median age was 67 years (range: 34-88), 51% were women and 71.5% had 0-1 ECOG scale. The 9.8, 11.4, 18 and 60% were CS I, II, III and IV. The most common metastatic sites were brain, bones, cervical and supraclavicular nodes. Patients with I CS underwent to lobectomy, and 59% of II and most III-IV CS received chemotherapy. The median follow-up was 4.9years, median OS was 1.4years (95%CI: 1.1-1.9) and 2 and 5years OS were 42% and 25%, respectively. The next table shows survival impact of blood ratios according CS. Optimal cut-off values were different according every CS of lung cancer, however in the IV CS group the cut-off of 2.6 and 0.31 for NLR and MLR showed significant survival impact on OS.
Our results suggest that exists different cut-off values for blood ratios according every clinical stage that needs to be explored among larger population data-bases to confirm it. In advanced disease, NLR and MLR show significant survival impact in this study.6f8b794f3246b0c1e1780bb4d4d5dc53
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.